Human medicines European public assessment report (EPAR): M-M-RVaxPro, measles, mumps and rubella vaccine (live), Date of authorisation: 05/05/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Venclyxto, venetoclax, Date of authorisation: 04/12/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 13, Status: Authorised

European Medicines Agency’s data protection notice for the use of EMA Authentication Services and Microsoft Entra ID

Records of data processing activity for EMA Authentication Services and Microsoft Entra ID

Human medicines European public assessment report (EPAR): Qdenga, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 05/12/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Date of authorisation: 22/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Date of authorisation: 09/12/2020, Revision: 7, Status: Authorised

CHMP PROM minutes for the meeting on 14 April 2025